Exact Sciences (EXAS) awards 28,063 restricted stock units to EVP Baranick

Rhea-AI Filing Summary

Baranick Brian reported acquisition or exercise transactions in this Form 4 filing.

EXACT SCIENCES CORP executive Brian Baranick received an equity award in the form of restricted stock units. On February 25, 2026, he was granted 28,063 restricted stock units, each representing a contingent right to receive one share of common stock at no purchase price.

These restricted stock units vest in four equal annual installments beginning on February 25, 2027, tying the award to multi‑year service. Following this grant, Baranick holds 103,874 shares of common stock directly, 795 shares indirectly through a 401(k) plan, and in aggregate an additional 28,063 restricted stock units.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Baranick Brian

Role EVP, GM, Precision Oncology

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	28,063	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 28,063 shares (Direct); Common Stock — 103,874 shares (Direct); Common Stock — 795 shares (Indirect, Held in 401(k) Plan)

Footnotes (1)

1. In addition to the shares of Common Stock reported on this Form 4, which total 104,669 shares, Mr. Baranick also holds, in the aggregate, an additional 28,063 restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vest in four equal annual installments beginning on February 25, 2027.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baranick Brian

(Last) (First) (Middle)

C/O EXACT SCIENCES CORP.

5505 ENDEAVOR LANE

(Street)

MADISON WI 53719

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXACT SCIENCES CORP [ EXAS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GM, Precision Oncology

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								103,874(1)	D
Common Stock								795	I	Held in 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	02/25/2026		A		28,063		(3)	(3)	Common Stock	28,063	$0	28,063	D

Explanation of Responses:

1. In addition to the shares of Common Stock reported on this Form 4, which total 104,669 shares, Mr. Baranick also holds, in the aggregate, an additional 28,063 restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.

2. Each restricted stock unit represents a contingent right to receive one share of common stock.

3. These restricted stock units vest in four equal annual installments beginning on February 25, 2027.

	/s/ Brian Baranick by Mark Busch, attorney-in-fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did EXACT SCIENCES (EXAS) executive Brian Baranick report on this Form 4?

Brian Baranick reported receiving 28,063 restricted stock units as an equity award. Each unit represents a contingent right to one share of EXACT SCIENCES common stock, granted at no purchase price on February 25, 2026.

How do the 28,063 restricted stock units for EXAS’s Brian Baranick vest?

The 28,063 restricted stock units vest in four equal annual installments. Vesting begins on February 25, 2027, meaning the award is spread over four years, encouraging longer-term retention and alignment with EXACT SCIENCES’ multi‑year performance.

How many EXACT SCIENCES shares does Brian Baranick hold after this Form 4?

After the reported transactions, Brian Baranick holds 103,874 shares of EXACT SCIENCES common stock directly and 795 shares indirectly in a 401(k) plan, according to the Form 4 holdings information and related footnote disclosure.

What is the relationship between the restricted stock units and EXACT SCIENCES common stock?

Each restricted stock unit reported by Brian Baranick represents a contingent right to receive one share of EXACT SCIENCES common stock. The units convert into shares only as they vest over four years starting February 25, 2027.

Did Brian Baranick buy or sell EXAS shares in the open market in this filing?

The filing describes a grant of 28,063 restricted stock units as an award, not an open-market purchase or sale. Other lines in the Form 4 update total common stock holdings without specifying separate buy or sell transactions.